OCULAR THERAPEUTIX, INC Net Income (Loss) Available to Common Stockholders, Diluted
OCULAR THERAPEUTIX, INC (OCUL) reported Net Income (Loss) Available to Common Stockholders, Diluted of -$86.97 million for the 12-month period ending 2023-12-31, per its 10-K filed 2026-02-05.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted · last filed 2026-02-05
- OCULAR THERAPEUTIX, INC net income (loss) available to common stockholders, diluted for the quarter ending 2023-12-31 was -$22.07M.
- OCULAR THERAPEUTIX, INC net income (loss) available to common stockholders, diluted for the quarter ending 2023-09-30 was -$21.56M.
- OCULAR THERAPEUTIX, INC net income (loss) available to common stockholders, diluted for the quarter ending 2022-12-31 was -$19.61M.
- OCULAR THERAPEUTIX, INC net income (loss) available to common stockholders, diluted for the quarter ending 2022-09-30 was -$21.89M.
- OCULAR THERAPEUTIX, INC net income (loss) available to common stockholders, diluted for fiscal 2023 was -$86.97M.
- OCULAR THERAPEUTIX, INC net income (loss) available to common stockholders, diluted for fiscal 2022 was -$80.28M.
- OCULAR THERAPEUTIX, INC net income (loss) available to common stockholders, diluted for fiscal 2021 was -$80.27M.
| Period end | Net Income (Loss) Available to Common Stockholders, Diluted 3 month | Net Income (Loss) Available to Common Stockholders, Diluted 6 month | Net Income (Loss) Available to Common Stockholders, Diluted 9 month | Net Income (Loss) Available to Common Stockholders, Diluted 12 month |
|---|---|---|---|---|
| 2023-12-31 | -$22.07M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-05 | -$43.63M derived: sum of 2 quarters · filed 2026-02-05 | -$86.97M 10-K · filed 2026-02-05 | |
| 2023-09-30 | -$21.56M 10-Q · filed 2024-11-14 | -$64.90M 10-Q · filed 2024-11-14 | ||
| 2022-12-31 | -$19.61M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | -$41.51M derived: sum of 2 quarters · filed 2025-03-03 | -$61.91M derived: sum of 3 quarters · filed 2025-03-03 | -$80.28M 10-K · filed 2025-03-03 |
| 2022-09-30 | -$21.89M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | -$42.29M derived: sum of 2 quarters · filed 2023-11-07 | -$60.67M 10-Q · filed 2023-11-07 | -$79.27M derived: sum of 4 quarters · filed 2024-03-11 |
| 2022-06-30 | -$20.40M 10-Q · filed 2023-08-07 | -$38.77M 10-Q · filed 2023-08-07 | -$57.37M derived: sum of 3 quarters · filed 2024-03-11 | -$77.44M derived: sum of 4 quarters · filed 2024-03-11 |
| 2022-03-31 | -$18.38M 10-Q · filed 2023-05-08 | -$36.98M derived: sum of 2 quarters · filed 2024-03-11 | -$57.04M derived: sum of 3 quarters · filed 2024-03-11 | -$77.83M derived: sum of 4 quarters · filed 2024-03-11 |
| 2021-12-31 | -$18.60M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-11 | -$38.67M derived: sum of 2 quarters · filed 2024-03-11 | -$59.45M derived: sum of 3 quarters · filed 2024-03-11 | -$80.27M 10-K · filed 2024-03-11 |
| 2021-09-30 | -$20.07M 10-Q · filed 2022-11-07 | -$40.85M derived: sum of 2 quarters · filed 2022-11-07 | -$61.67M 10-Q · filed 2022-11-07 | |
| 2021-06-30 | -$20.78M 10-Q · filed 2022-08-08 | -$41.60M 10-Q · filed 2022-08-08 | ||
| 2021-03-31 | -$20.82M 10-Q · filed 2022-05-09 | |||
| 2020-09-30 | -$14.65M 10-Q · filed 2021-11-08 | |||
| 2019-09-30 | -$23.50M 10-Q · filed 2020-11-05 | |||
| 2019-03-31 | -$19.99M 10-Q · filed 2020-05-08 | |||
| 2018-03-31 | -$13.77M 10-Q · filed 2019-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |